A GAME-CHANGER IN THE BATTLE AGAINST
ALZHEIMER’S
Exciting developments are on the horizon in the fight against Alzheimer's disease, as a ground- breaking drug called Donanemab emerges as a turning point in the quest for effective treatments.
F
ollowing a global trial that confirmed its ability to slow cognitive decline, the antibody medicine is proving to be a
promising option for combating this devastating form of dementia.
Donanemab operates specifically in the early stages of Alzheimer's, targeting a protein that accumulates in the brains of those affected by the disease.
Although it does not present a cure, the results published in the journal JAMA indicate a ground- breaking breakthrough where Alzheimer's may be treated effectively. This development has sparked hope among charities, paving the way for a new era of Alzheimer's treatment.
The UK's drugs watchdog has initiated an assessment of Donanemab for possible integration into the National Health Service (NHS). This potential breakthrough is expected to significantly impact the lives of those affected by Alzheimer's disease, especially in its early stages.
28
scottishpharmacist.com
During the trials involving 1,736 individuals aged between 60 and 85 with early-stage Alzheimer's, the drug showcased notable benefits. It appears to have slowed the progression of the disease by approximately one-third, enabling patients to retain a higher level of independence in their day-to-day activities, such as meal preparation and hobbies.
Despite the promising results, it's essential to acknowledge that these drugs are not without risks. The trial revealed brain swelling as a common side effect in up to a third of patients. While most cases resolved without symptoms, there were instances of dangerous swelling in the brain leading to fatalities.
Donanemab, produced by Eli Lilly, shares similarities with Lecanemab, developed by Eisai and Biogen, which garnered global attention for its success in slowing the progression of the disease. While these drugs show enormous potential, experts caution that further research is necessary to fully understand their effects over an extended period.
The introduction of a drug like Donanemab marks a significant stride in the journey toward finding effective treatments for Alzheimer's disease.
The ability to target and clear the brain of the amyloid protein signifies a remarkable step in transforming Alzheimer's into a treatable condition.
Looking ahead, the hope is to develop a "statin for the brain," a pill that can be taken regularly to clear these proteins from the brain and reduce the risk of dementia-related diseases.
While the specific cost of donanemab and the time it may take to gain approval in the UK remain uncertain, having multiple drugs in this domain can drive competition, potentially leading to more accessible pricing.
The UK's drug watchdog, NICE, is actively appraising Donanemab for its potential use in treating mild cognitive impairment or mild dementia caused by Alzheimer's disease.
TRIALS SHOW THE PROGRESSION OF THE DISEASE IS SLOWED BY APPROXIMATELY ONE-THIRD
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
